MS Research Update — August 28, 2026 (Updated)
Updated Thesis
Morgan Stanley is a leading financial holding company offering a comprehensive suite of financial solutions across Institutional Securities, Wealth Management, and Investment Management. The company has demonstrated strong recent performance with revenue growth of 22.4% and earnings growth of 57.7% in the most recent quarter, supported by robust capital markets activity. Despite trading at a premium to its historical valuation multiples, the stock is undervalued relative to a blended fair value estimate of $310.79, implying 44.7% upside.
The investment grade as of this refresh is B — solid business quality. High-tier business, expensive-tier valuation relative to historical multiples but undervalued versus blended fair value.
Key Metrics at a Glance
- Revenue growth: +22.4% year over year
- Net margin: 16.0%
- Fair value upside: +44.7% to our estimate of $311
Current price: $214.83
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Morgan Stanley remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full MS research →](/stocks/MS)